Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
The All India Institute of Medical Sciences on Wednesday flagged concern over a spurt in…
The Federation of Resident Doctors’ Association (FORDA) strongly condemns the National Board of Examinations’ arbitrary…
Dismissing the recent claims of linking eggs to cancer risk, the Food Safety and Standards…
Across India’s food landscape, quiet substitutions have begun shaping what reaches the plate. The cubes…
The Association of Healthcare Providers (India) (AHPI), the apex body representing nearly 20,000 hospitals across…
In a major advancement for the surgical landscape in India, Apollo Spectra Hospital has unveiled…